About Augmenix
Augmenix is a company based in Waltham (United States) founded in 2008 was acquired by Boston Scientific in September 2018. Augmenix has raised $46.6 million across 7 funding rounds from investors including Boston Scientific, Varian and Pinnacle Ventures. The company has 153 employees as of December 31, 2018. Augmenix operates in a competitive market with competitors including AmacaThera, Regentis Biomaterials, LifeSprout, Biosyntech and ECM Therapeutics, among others.
- Headquarter Waltham, United States
- Employees 153 as on 31 Dec, 2018
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Augmenix, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$46.6 M (USD)
in 7 rounds
-
Latest Funding Round
$6 M (USD), Series E
Jul 18, 2016
-
Investors
Boston Scientific
& 7 more
-
Employee Count
153
as on Dec 31, 2018
-
Acquired by
Boston Scientific
(Sep 06, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Augmenix
Augmenix has successfully raised a total of $46.6M across 7 strategic funding rounds. The most recent funding activity was a Series E round of $6 million completed in July 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series E — $6.0M
-
First Round
First Round
(29 Feb 2008)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2016 | Amount | Series E - Augmenix | Valuation |
investors |
|
| Jul, 2014 | Amount | Series D - Augmenix | Valuation |
investors |
|
| May, 2011 | Amount | Series C - Augmenix | Valuation |
investors |
Investors in Augmenix
Augmenix has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Boston Scientific, Varian and Pinnacle Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Late stage tech-focused VC firm funding companies in the US
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Augmenix
Financial Statements - Augmenix
Augmenix Comparisons
Competitors of Augmenix
Augmenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AmacaThera, Regentis Biomaterials, LifeSprout, Biosyntech and ECM Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Injectable hydrogel platform developed for therapeutic medical applications.
|
|
| domain | founded_year | HQ Location |
Regentis Biomaterials is focused on tissue repair hydrogel technology.
|
|
| domain | founded_year | HQ Location |
Synthetic soft tissue substitutes for cosmetics and reconstructive surgery
|
|
| domain | founded_year | HQ Location |
Biotherapeutic thermogels are developed for tissue repair applications.
|
|
| domain | founded_year | HQ Location |
Diagnostic and therapeutic products from extracellular matrix are developed.
|
Frequently Asked Questions about Augmenix
Augmenix was founded in 2008.
Augmenix is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Augmenix is a funded company, having raised a total of $46.6M across 7 funding rounds to date. The company's 1st funding round was a Series C of $15M, raised on Feb 29, 2008.
As of Dec 31, 2018, the latest employee count at Augmenix is 153.
Provider of a hydrogel spacer for prostate cancer radiation therapy. This hydrogel is injected to create space between the rectum and prostate, reducing radiation exposure to the rectum during treatment. The procedure aims to minimize urinary, sexual, and bowel side effects associated with radiation therapy. The hydrogel is made of polyethylene glycol (PEG) and is intended for temporary use during radiotherapy. Potential complications, though rare, include injection site pain, inflammation, and other issues. Patients should discuss risks and benefits with their physician before treatment.
Augmenix's top competitors include AmacaThera, LifeSprout and Regentis Biomaterials.
Augmenix has 8 investors. Key investors include Boston Scientific, Varian, Pinnacle Ventures, Excelestar Ventures, and Catalyst Health Ventures.